The pharmaceutical company Merck announced on Thursday, July 16th, 2026, that it has received FDA approval for Lipfendra, a daily pill designed to treat high levels of LDL cholesterol, often referred to as "bad cholesterol." Lipfendra is a PCSK9 inhibitor and can be taken alongside statins or as an alternative for patients who do not tolerate statins well.

Statins have been the primary treatment for high cholesterol in the US for decades but sometimes cause side effects such as muscle aches and may not sufficiently lower LDL levels to meet recommended goals. Dr. Paja Banka, Merck's associate vice-president for global clinical development and a pediatric cardiologist, emphasized the importance of this development, noting that "seventy per cent of patients are not getting to their LDL goal."

According to new guidelines issued in March by the American College of Cardiology and the American Heart Association, acceptable LDL cholesterol levels vary based on patient history and risk. Generally, levels should remain below 100 mg/dL. For individuals with atherosclerotic cardiovascular disease (ASCVD) at very high risk, the LDL-C goal is less than 55 mg/dL for secondary prevention of cardiac events.

Dr. Banka also stated that Lipfendra's side effects appeared minimal in clinical trials, with no reports of muscle aches, a common issue with statins. The drug can be used in conjunction with statins or, in some cases, as a standalone treatment.

This approval provides a new option for patients struggling to reach their cholesterol targets and may improve cardiovascular health outcomes.

Sources